Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2862)	6/1/2010 11:50:04 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ABII is up 10.73% on moderate volume. bigcharts.marketwatch.com ABII will be presenting 32 scientific abstracts at the ASCO meeting, evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel injectable suspension. The clinical findings of this nab-driven chemotherapy will be presented in the treatment of multiple tumor types, including some of the most difficult-to-treat cancers.<g> finance.yahoo.com The stock has already closed its March 17 UG and is now facing again resistance at the $50 level. Although ABII has been burning its cash at a good clip, it finished the 2008 Yr.with a strong 4thQ showing a 14% improvement of revenues and earnings on the black at $0.21 vs. loss of $0.21 in 2008 The 1stQ results were even better with a 53% improvement on revenues and earnings again on the black at $0.22 vs. loss of $0.14 in 2009 It is expected that the pending 2ndQ )June) will also show good comparison results. The insiders reportedly hold > 80% There is no ACTAY, the SR increased 13% the last month to about 5x its ADV. With further good news, I will put a target at the $65 to $70 level.<g> bigcharts.marketwatch.com Bernard